Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
0.450
+0.020 (4.63%)
At close: Dec 20, 2024, 4:00 PM
0.468
+0.018 (4.11%)
After-hours: Dec 20, 2024, 6:08 PM EST
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
11.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sol-Gel Technologies | 11.71M |
Jaguar Health | 10.48M |
Immuron | 3.27M |
Lyra Therapeutics | 1.47M |
Talphera | 281.00K |
SNSE News
- 24 days ago - Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference - GlobeNewsWire
- 3 months ago - Sensei Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 4 months ago - Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 months ago - Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - GlobeNewsWire